Main overview
- PharmBot AI has submitted written evidence to the UK Parliament detailing the role of AI in pharmacy.
- It includes real implementation data from 76 Pharmacy First consultations.
- The company says community pharmacies remain underrepresented in national digital health policies.
farm bot AI has given written evidence to the House of Lords Science and Technology Committee as part of its ongoing inquiry into ‘Innovation in the NHS: Personalized Medicine and Artificial Intelligence’.
of A UK-based clinical AI company developing AI-enabled decision support infrastructure for pharmacies has published evidence on the role of AI-assisted clinical workflows in community pharmacy.
in spite of Although they serve millions of patients every day through around 10,000 pharmacies across the UK, they have received relatively limited attention in national digital health policy.
Submission memod argues that digital innovation in community pharmacy remains relatively limited compared to other healthcare sectors and this is a missed opportunity for the NHS.
The evidence is AIVAe is PharmBot AI’s clinical assistant platform across 76 structured clinical consultations within the NHS Pharmacy First programme.
Preliminary analysis of consultation content Approximately 15 to 20 minutes of time were saved per visit, indicating improved consistency and completeness of clinical documentation.
The company calls it a “community pharmacy.” Despite its size and daily contact with millions of patients, it remains underrepresented in national digital health policies.
Asif Mukhtar, Founder and CEO PharmBot AI said: “This study asks exactly the right question, not whether AI works in the lab, but why it is so rare for it to actually work within the NHS.”
“Our proposals provide concrete, evidence-based answers from local pharmacies. AI fails when built outside of clinical workflows and then introduced into clinical workflows. Community pharmacy, despite regularly serving more patients than almost any other sector of the NHS, is not consistently involved in these policy discussions.
“I hope this post will help change that situation. Evidence from our Pharmacy First consultation suggests that when AI is truly integrated into workflows from the beginning, the benefits are measurable and meaningful. ”
The company isWe believe clinical governance must be the foundation of responsible AI use, not an afterthought.
The House of Lords Science and Technology Committee launched an inquiry in March 2026 to investigate why the NHS is struggling to implement UK life science innovations. Personalized medicine and AI as a case study.
